An Investigator-Initiated, Phase II, Multicenter, Open-Label, Single-Arm, Prospective Clinical Trial to Evaluate the Efficacy and Safety of Alternating Bortezomib-Based Regimens in Combination With DaratUMumab Followed by Maintenance With Daratumumab in the Frontline Setting of Primary Plasma CEll L

This study tests a combination treatment for primary plasma cell leukemia (pPCL), a rare and aggressive blood cancer. The treatment combines two types of cancer drugs — bortezomib-based regimens and daratumumab — used in an alternating schedule, followed by daratumumab as maintenance therapy. **You may be eligible if...** - You are between 18 and 80 years old - You have been newly diagnosed with primary plasma cell leukemia (a rare, aggressive form of multiple myeloma) - Your disease meets specific measurable criteria for blood and bone marrow involvement - Your heart, liver, and kidney function meet the required thresholds - You are willing to use contraception if applicable **You may NOT be eligible if...** - You have received any prior treatment for this cancer - You have serious liver failure, uncontrolled infections, or active hepatitis - You have had a recent heart attack, significant heart disease, or serious clotting problems - You are pregnant or breastfeeding - You are allergic to any of the study drugs Talk to your doctor to see if this trial is right for you.